Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Fenna Phibbs

Neurology Nashville, TN Medical Doctor

NPI 1306987730 CMS profile 1168766

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$14,835

29 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$52,749 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Fenna Phibbs of Nashville, TN is reported in the CMS Open Payments database as having received $14,835 across 29 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $52,749 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $95 2
2022 General $31 1
2021 General $2,138 5
2020 General $450 1
2019 General $12,121 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fenna Phibbs
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Fenna Phibbs were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Fenna Phibbs Neurology median Middle half National median
2019 $12,121 $474 $118–$2,177 $163
2020 $450 $367 $82–$2,309 $114
2021 $2,138 $438 $104–$2,547 $132
2022 $31 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $95 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $5,471 13 payments
  2. Medtronic USA, Inc. $5,450 2 payments
  3. Boston Scientific Corporation $3,425 11 payments
  4. Abbott Laboratories $400 1 payment
  5. Medtronic, Inc. $65 1 payment
  6. Ge Healthcare $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $7,563 6 payments
  2. Grant $5,000 1 payment
  3. Travel and Lodging $1,598 9 payments
  4. Food and Beverage $674 13 payments
Products named General payments · program years 2019–2024
  1. ACTIVA $5,450 2 payments
  2. DUOPA $4,371 12 payments
  3. GENERAL DBS Dbs $2,372 3 payments
  4. GENERAL THERAPIES $971 5 payments
  5. Proclaim IPG $400 1 payment
  6. PERCEPT PC BRAINSENSE $65 1 payment
  7. General - DBS $31 1 payment
  8. GENERAL DBS Pain Management $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,416

Median for Neurology: 833

Drug cost

$709,950

Median for Neurology: $202,670

Branded share of claims

50.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 19 $199,067
Austedo Deutetrabenazine Brand 26 $112,407
Droxidopa Generic 12 $81,447
Rytary Carbidopa/Levodopa Brand 36 $60,276
Nuplazid Pimavanserin Tartrate Brand 11 $54,173
Tetrabenazine Generic 17 $39,365
Carbidopa-Levodopa Carbidopa/Levodopa Brand 549 $33,378
Nourianz Istradefylline Brand 13 $23,167
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 247 $17,508
Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone Brand 39 $15,906

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$36,368

Medicare's payments for the services billed

Medicare patients

240

Average age 72

Services billed

594

92 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Depression 42%
Ischemic heart disease 30%
Diabetes 28%
Chronic kidney disease 23%
Cancer 20%
Alzheimer's or dementia 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record